Drug use : Lifetime prevalence (%) of drug use among all adults (ages 15-64 years) in Norway and the EU-27

Lifetime prevalence (%) of drug use among all adults (ages 15-64 years) in Norway and the EU-27 (source: EMCDDA, 2007)

Country	Year	Age range	Cannabis	Cocaine^a	Amphetamines	Ecstasy^b	LSD
Austria	2004	15-64	20,1	2,3	2,4	3	1,7
Belgium	2004	15-64	13	-	-	-	-
Bulgaria	2005	18-60	4,4	1,1	1,4	1,3	0,8
Cyprus	2006	15-64	6,6	1,1	0,8	1,6	0,9
Czech-Republic	2004	18-64	20,6	1,1	2,5	7,1	1,4
Denmark	2005	16-64	36,5	4	6,9	1,8	1,7
Estonia	2003	-	-	-	-	-	-
Finland	2004	15-64	12,9	1,2	1,9	1,4	0,7
France	2005	15-64	30,6	2,6	1,4	2	1,5
Germany	2003	18-59	24,5	3,2	3,4	2,4	2,5
Greece	2004	15-64	8,9	0,7	0,1	0,4	0,3
Hungary	2003	18-54	9,8	1	2,5	3,1	1,7
Ireland	2002-03	15-64	17,4	3	3	3,7	2,9
Italy	2005	15-64	29,3	6,6	2,4	2,5	3,1
Latvia	2003	15-64	10,6	1,2	2,6	2,4	1,1
Lithuania	2004	15-64	7,6	0,4	1,1	1	0,3
Luxembourg	1998	15-64	12,9	0,2	-	1,2	1,4
Malta	2001	18-64	3,5	0,4	0,4	0,7	0,5
Netherlands	2005	15-64	22,6	3,4	2,1	4,3	1,4
Norway	2004	15-64	16,2	2,7	3,6	1,8	1,1
Poland	2002	16-64	7,7	0,8	1,9	0,7	1,2
Portugal	2001	15-64	7,6	0,9	0,5	0,7	0,4
Romania	2004	15-64	1,7	0,4	0,2	0,3	0,2
Slovakia	2004	15-64	15,6	1,1	1,5	4	-
Spain	2005-06	15-64	28,6	7	3,4	4,4	-
Sweden	2006	16-64	12	-	-	-	-
United-Kingdom	2004	-	29,6	6,5	11,7	6,7	5,9

- : no data available

^a Cocaine any form.

^b For Spain: ecstasy and other designer drugs.

Remarks

This table aims to present an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as reference point for the 1993 survey.

In surveys with small sample sizes results should be interpreted with caution.

Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15-64, young adults: 15-34). In countries where age ranges are more restrictive, prevalence estimates tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups.

For original EMCDDA data see: Lifetime prevalence of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population (EMCDDA Statistical bulletin 2007)